Health care leaders joined a virtual panel to discuss the effects of COVID-19 and more. Photo by Dwight C. Andrews/Greater Houston Convention and Visitors Bureau

There has been an undeniable paradigm shift in the health care industry due to COVID-19 as well as the growth of technology. A group of professionals sat down to discuss what in particular has changed for the industry as a whole as well as at local institutions.

At a panel for Venture Houston, a two-day conference put on by the HX Venture Fund on February 4th and 5th, a few health care professionals weighed in on all the changes to the industry for the startups, investors, corporations, and more who attended the virtual event. Here are some significant overheard moments from the virtual panel — Thinking Past a COVID World.

“For most of health care, this last year has been probably five years of rapid cycle re-innovation and movement forward — particularly in the digital realm.”

Marc Boom, president and CEO of Houston Methodist. From rapid adoption of telemedicine to developing a COVID-19 vaccine in less than a year, health care has seen rapid growth. However, there's fine tuning still needed, Boom continues.

"At the end of the day there's only so much we can do virtually," he adds.

“The most incredible thing was how the vaccines got developed so quickly.”

Chris Rizik, CEO of Renaissance Venture Partners. A large portion of the industry wasn't excited about RNA vaccines, but the COVID-19 vaccines might have changed some minds. It took 11 months to get it out into the world, but 10 of that was purely regulatory, he adds.

"One of the sustaining changes of the COVID-19 pandemic is I think RNA vaccines are here to stay."

​— Paul Klotman, executive dean of Baylor College of Medicine. Klotman adds that the vaccine's trials were so impressively quick because there were just so many COVID patients sick and eligible to enroll.

“I think one of the things the TMC institutions did really well was to decide really early on was to share data.”

Boom says, adding that the TMC represents around 70 percent of Houston's adults and around 90 percent of the city's pediatric patients. This opportunity for data is "one of the most robust sources of real-time data."

"Yes, you're going to compete clinically, but there's a lot of collaboration to be done especially during a pandemic," Boom says of the TMC's member organizations prioritizing collaboration with data sharing.

“Houston has done better than almost all major metropolitan areas because we have came together as a city and a community.”

Klotman says, adding that the vast patient base the TMC is key.

"There's a huge opportunity here for early biotech development," he says. "Because there are so many patients, there are huge opportunities to do new trials."

“The real challenge is for investors to be in tune to know what’s here to stay, and to invest around that."

Rizik says, adding that 2020 was the biggest year for health care investment with more money going into deals, rather than more deals occuring.

“We’re seeing a huge uptick in people interested in health professions, thanks to COVID.”

Boom says of the industry's workforce, which has usually been hard to recruit and grow.

“The medical school communities are all racing to change the way we teach and the kind of information we teach.”

Klotman says of the future of the workforce.

“Unlike most industries, technology is tended to be cumbersome in health care.

​— Boom says adding that new technology means added costs and slowed down processes that can't replace the human touch. Houston Methodist is looking for innovations that don't take health care professionals away from patients.

“If there’s anything this last year has shown us is that as fast as we thought we were going, we need to go faster. We’re excited to work with companies with great ideas.”

— Boom says of the future of tech in health care. "I think we're on a very transformational era in digital health right now — but there's a lot of work to be done still."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”